Board of Directors
Q-linea’s BoD consist of a combination of entrepreneurs, inventors and industrial experienced persons representing the major owners of the company, and providing active support to the management.
Holdings as of April 24, 2025.
Erika Kjellberg Eriksson
Director since 2012, chairman of the board since 2018
Erika Kjellberg Eriksson has held board assignments and senior positions in pharmaceutical, biotech and medtech companies for more than 25 years. She has extensive experience from working in both listed and unlisted companies and vast board experience.
Born: 1962
Education: BSc in Economics, Uppsala University (1985).
Other current assignments: Erika Kjellberg Eriksson is CEO of Nexttobe AB, chairman of the board of directors of Linum AB, Brixton Medical AB, Lumina Adhesives AB, Lokon Pharma AB, and Tanea Medical AB, Director of Findolon AB.
Holdings in the Company: Erika Kjellberg Eriksson owns 10,199,000 shares and 5,000,000 warrants (TO1) in the Company.
She is independent in relation to the company and its management, but not in relation to major shareholders.
Finn Sander Albrechtsen
Director since 2023
Finn Sander Albrechtsen has more than 16 years of international leadership experience from the life science and diagnostics industry. This includes seven years with Dako and Agilent Technologies in positions focused on product development, from portfolio- and project management to leading the global R&D function. Between 2015 and 2021, Finn was VP of R&D and Business Development for the Microbiology division within Thermo Fisher Scientific.
Born: 1967
Education: BSc in Electrical Engineering, Technical University of Denmark.
Other ongoing assignments: Finn Sander Albrechtsen is Head of Global R&D at SSI Diagnostica Group and a member of the board of directors of Panacea Diagnostics Ltd.
Holdings in the Company: Finn Sander Albrechtsen owns 3,950,000 shares and 1,925,000 warrants (TO1) in the company.
He is independent in relation to the company and its management and in relation to major shareholders.
Hans Johansson
Director since 2018
Hans Johansson has extensive experience and a broad contact network from his previous roles in the life sciences and diagnostics industry, most recently as vice president, head of Companion Diagnostics at Thermo Fisher’s Speciality Diagnostics Group. His previous positions include vice president global marketing and business development at Thermo Fisher’s Immuno Diagnostics Division, CEO of Pyrosequencing/Personal Chemistry (now Biotage), and head of laboratories at Pharmacia Biotechnology AB.
Born: 1954
Education: MSc in chemical engineering
Other ongoing assignments: Hans Johansson is chairman of the board of directors of Myrtila AB and a member of the board of directors of Immunovia AB (publ).
Holdings in the Company: Hans Johansson owns 929,356 shares and 452,914 warrants (TO1) in the Company.
He is independent in relation to the company and its management and in relation to major shareholders.
Karin Fischer
Director since 2023
Karin Fischer has more than 15 years of global commercial experience from both strategic and operative positions. She has also been stationed in the US. Karin has worked for companies such as Johnson & Johnson, Getinge, Xvivo Perfusion and RLS Global. She was CEO for more than four years at RLS Global, listed at Nasdaq First North.
Born: 1976
Education: BSc in Business administration and Economics, University of Aberdeen.
Other ongoing assignments: Karin Fischer is currently CEO at Biolin Scientific AB, a company within the AddLife group.
Holdings in the Company: Karin Fischer does not own any shares in the Company.
She is independent in relation to the company and its management and in relation to major shareholders.
Mario Gualano
Director since 2020
Mario Gualano has more than 25 years of commercial, technical and operational experience in the microbiology and diagnostics industry, including 15 years in international leadership roles with Thermo Fisher Scientific. During his time with Thermo Fisher Scientific, he led Thermo Fisher Scientific’s Specialty Diagnostics Group in APAC and, most recently, was the President of the Microbiology division.
Born: 1969
Education: PhD in Microbiology and Immunodiagnostics and a MBA from Henley Management College.
Other ongoing assignments: Strategic Advisor, BBI Solutions Ltd.
Holdings in the Company: Mario Gualano does not own any shares in the Company.
He is independent in relation to the company and its management and in relation to major shareholders.
Jonas Jarvius
Director since 2024
Jonas Jarvius has over 20 years of experience in research and development in molecular medicine and molecular biology detection. He has co-founded several companies and is one of the founders of Q-linea. He served as CEO of the company from 2008 to 2024. For many years, he has been active in leading positions in various biotech companies and has been responsible for projects concerning e.g. molecular identification for security applications as well as manufacturing and development of medical devices. He also has experience in certification according to ISO-13485, a standard for quality management intended for medical devices. He has also been involved in a number of biotech startups.
Born: 1971
Education: PhD in Molecular Medicine and a Master’s degree in Medicine, Uppsala University.
Other ongoing assignments: President, CEO and Director of Bifrost Biosystems, Inc. Member of the board of directors of Umbrella Science AB.
Holdings in the Company: Jonas Jarvius owns 6,326,978 shares in the Company.
He is independent in relation to the company and its management and in relation to major shareholders.